A patient is receiving hydroxychloroquine therapy but tells the nurse that she has never traveled out of her city. The nurse knows that a possible reason for this drug therapy is which of these conditions?

Choice A reason: Using a corticosteroid inhaler like fluticasone for asthma attacks is incorrect. Corticosteroids reduce inflammation over days, not immediately, and are for maintenance. Acute attacks require short-acting beta-agonists like albuterol for rapid bronchodilation, indicating a need for further patient education on inhaler roles.

Choice B reason: Cleaning the inhaler casing weekly with warm soapy water is correct. This prevents drug residue buildup, ensuring proper dose delivery and reducing infection risk. Removing the canister and drying the casing properly maintains inhaler function, reflecting appropriate understanding of maintenance.

Choice C reason: Rinsing the mouth with water and spitting it out after using a corticosteroid inhaler is correct. This removes residual drug, preventing oral candidiasis by reducing fungal growth in the oral cavity. It reflects proper understanding of post-inhalation hygiene, requiring no further instruction.

Choice D reason: Gargling and swallowing after using a corticosteroid inhaler is incorrect. Swallowing residual corticosteroid can increase systemic absorption, raising the risk of side effects like adrenal suppression. Rinsing and spitting out is necessary to minimize oral thrush and systemic effects, indicating a need for correction.

Choice A reason: The purpose of multiple drugs in tuberculosis treatment is not to hope one works but to ensure comprehensive bacterial eradication. Combination therapy targets different aspects of Mycobacterium tuberculosis, preventing resistance and ensuring efficacy, as single-drug therapy is ineffective and promotes resistant strains.

Choice B reason: Multiple drugs do not primarily reduce side effects; they increase the likelihood of adverse effects due to cumulative toxicity (e.g., hepatotoxicity from isoniazid and rifampin). The rationale for combination therapy is to enhance efficacy and prevent resistance, not to mitigate side effects, making this incorrect.

Choice C reason: Combination therapy (e.g., isoniazid, rifampin, ethambutol, pyrazinamide) enhances efficacy by targeting different bacterial populations and metabolic states of Mycobacterium tuberculosis. This synergistic approach ensures rapid bacterial killing, prevents resistance, and shortens treatment duration, making it the standard for effective tuberculosis management.

Choice D reason: The use of multiple drugs is not because drugs are becoming resistant but to prevent resistance development. Combination therapy overwhelms Mycobacterium tuberculosis with multiple mechanisms, reducing the chance of resistant mutants surviving. Resistance occurs with inadequate or monotherapy, not as a rationale for combination therapy.